Related Experiment Videos
Pharmacokinetics of rapamycin
1Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
Transplantation Proceedings
|April 1, 1996
Summary
Rapamycin (RAPA) primarily distributes into erythrocytes, showing a long half-life and dose-proportional trough concentrations. These levels correlate with immunosuppressive effects and side effects, guiding therapeutic monitoring.
Area of Science:
- Pharmacology and Drug Metabolism
- Immunopharmacology
Background:
- Understanding the pharmacokinetic profile of Rapamycin (RAPA) is crucial for optimizing its immunosuppressive therapy.
- Previous studies have indicated RAPA's potential in various immunosuppressive applications, necessitating further investigation into its drug behavior.
Purpose of the Study:
- To investigate the distribution, pharmacokinetics, and therapeutic range of Rapamycin (RAPA).
- To establish a basis for developing therapeutic monitoring protocols for RAPA.
Main Methods:
- Analysis of Rapamycin (RAPA) distribution, focusing on sequestration in erythrocytes and whole blood concentrations.
- Pharmacokinetic assessments including half-life determination and 24-hour trough concentration measurements using High-Performance Liquid Chromatography (HPLC).
- Dose-concentration proportionality studies and correlation analyses with immunosuppressive efficacy and side effects.
Main Results:
- The majority of Rapamycin (RAPA) is sequestered in erythrocytes, leading to measurable whole blood concentrations.
- RAPA exhibits a prolonged half-life in both humans and animals, with detectable trough concentrations at immunosuppressive doses.
- A direct proportionality exists between RAPA trough concentrations and administered dose, which also correlates with efficacy and adverse events.
Conclusions:
- Rapamycin (RAPA) distribution is primarily within erythrocytes, influencing whole blood pharmacokinetic measurements.
- The long half-life and dose-proportionality of RAPA support the feasibility of therapeutic drug monitoring.
- Established trough concentration-efficacy and trough concentration-toxicity relationships provide a foundation for clinical RAPA monitoring protocols.